Maravai LifeSciences Holdings Inc. (MRVI) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
10770 WATERIDGE CIRCLE SUITE 200 SAN DIEGO, CA 92121 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 285,053 | 322,399 | 578,157 | 573,171 | 561,691 | 574,962 | |||
| Cash and cash equivalent | 285,053 | 322,399 | 578,157 | 573,171 | 561,691 | 574,962 | |||
| Receivables | 28,493 | 38,520 | 28,873 | 38,651 | 36,685 | 54,605 | |||
| Inventory, net of allowances, customer advances and progress billings | 49,773 | 50,082 | 50,409 | 49,294 | 49,846 | 51,397 | |||
| Inventory | 49,773 | 50,082 | 50,409 | 49,294 | 49,846 | 51,397 | |||
| Derivative instruments and hedges, assets | 6,575 | ||||||||
| Government assistance, asset | 608 | ✕ | |||||||
| Other undisclosed current assets | 12,963 | 18,145 | 21,659 | 17,063 | 19,662 | 18,948 | |||
| Total current assets: | 376,282 | 429,146 | 679,098 | 685,362 | 667,884 | 699,912 | |||
| Noncurrent Assets | |||||||||
| Intangible assets, net (including goodwill) | 359,459 | 354,835 | 373,648 | 533,278 | 540,147 | 547,016 | |||
| Goodwill | 159,878 | 159,878 | 171,790 | 326,029 | 326,029 | 326,029 | |||
| Intangible assets, net (excluding goodwill) | 199,581 | 194,957 | 201,858 | 207,249 | 214,118 | 220,987 | |||
| Other noncurrent assets | 57,582 | 59,789 | 60,914 | 63,465 | 74,982 | 77,622 | |||
| Other undisclosed noncurrent assets | 166,428 | 164,474 | 164,555 | 165,503 | 161,628 | 162,900 | |||
| Total noncurrent assets: | 583,469 | 579,098 | 599,117 | 762,246 | 776,757 | 787,538 | |||
| TOTAL ASSETS: | 959,751 | 1,008,244 | 1,278,215 | 1,447,608 | 1,444,641 | 1,487,450 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 54,128 | 36,407 | 38,498 | 40,719 | 35,405 | 60,237 | |||
| Accounts payable | 9,525 | ||||||||
| Accrued liabilities | 44,603 | 36,407 | 38,498 | 40,719 | 35,405 | 60,237 | |||
| Deferred revenue | 2,756 | 2,375 | 1,834 | 2,078 | 2,210 | 3,360 | |||
| Debt | 6,274 | 6,232 | 6,190 | 6,150 | 6,112 | 6,073 | |||
| Other undisclosed current liabilities | 11,957 | 16,719 | 19,605 | 15,295 | 17,798 | ||||
| Total current liabilities: | 63,158 | 56,971 | 63,241 | 68,552 | 59,022 | 87,468 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 320,380 | 321,598 | 547,610 | 548,610 | 549,607 | 550,604 | |||
| Long-term debt, excluding current maturities | 289,499 | 290,492 | 516,283 | 517,083 | 517,893 | 518,707 | |||
| Finance lease, liability | 30,881 | 31,106 | 31,327 | 31,527 | 31,714 | 31,897 | |||
| Liabilities, other than long-term debt | 45,940 | 52,466 | 54,237 | 54,032 | 58,623 | 59,494 | |||
| Deferred income tax liabilities | 1,974 | ||||||||
| Other liabilities | 43,966 | 52,466 | 54,237 | 54,032 | 58,623 | 59,494 | |||
| Total noncurrent liabilities: | 366,320 | 374,064 | 601,847 | 602,642 | 608,230 | 610,098 | |||
| Total liabilities: | 429,478 | 431,035 | 665,088 | 671,194 | 667,252 | 697,566 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 300,614 | 325,292 | 345,140 | 436,933 | 410,659 | 416,753 | |||
| Additional paid in capital | 186,797 | 181,874 | 175,581 | 168,337 | 134,482 | 128,503 | |||
| Accumulated other comprehensive income | 324 | ||||||||
| Retained earnings | 110,946 | 140,891 | 167,036 | 266,074 | 273,659 | 285,737 | |||
| Other undisclosed equity, attributable to parent | 2,547 | 2,527 | 2,523 | 2,522 | 2,518 | 2,513 | |||
| Equity, attributable to noncontrolling interest | 229,659 | 251,917 | 267,987 | 339,481 | 366,730 | 373,131 | |||
| Total equity: | 530,273 | 577,209 | 613,127 | 776,414 | 777,389 | 789,884 | |||
| TOTAL LIABILITIES AND EQUITY: | 959,751 | 1,008,244 | 1,278,215 | 1,447,608 | 1,444,641 | 1,487,450 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 46,850 | 56,406 | 65,200 | 73,400 | 64,179 | 74,141 | ||
| Cost of revenue | (39,125) | (37,444) | (36,826) | (38,271) | (38,335) | (35,108) | ||
| Gross profit: | 7,725 | 18,962 | 28,374 | 35,129 | 25,844 | 39,033 | ||
| Operating expenses | (56,887) | (57,722) | (197,666) | (45,836) | (44,705) | (49,538) | ||
| Other undisclosed operating income (loss) | 630 | 178 | 1,195 | 3,355 | ||||
| Operating loss: | (49,162) | (38,130) | (169,114) | (9,512) | (18,861) | (7,150) | ||
| Nonoperating income (expense) | 3,249 | 6,079 | 7,143 | 4,524 | 7,316 | 7,508 | ||
| Investment income, nonoperating | 3,225 | 6,036 | 7,071 | 7,086 | 7,210 | 7,459 | ||
| Other nonoperating income (expense) | 24 | 43 | 72 | (2,562) | 106 | 49 | ||
| Interest and debt expense | (6,778) | (14,450) | (13,634) | (11,939) | (10,864) | (15,400) | ||
| Loss from continuing operations before equity method investments, income taxes: | (52,691) | (46,501) | (175,605) | (16,927) | (22,409) | (15,042) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | (1) | (39) | 671,228 | |||||
| Income (loss) from continuing operations before income taxes: | (52,691) | (46,502) | (175,644) | (16,927) | (22,409) | 656,186 | ||
| Income tax expense (benefit) | (162) | 7 | (311) | 2,435 | (271) | (766,168) | ||
| Net loss: | (52,853) | (46,495) | (175,955) | (14,492) | (22,680) | (109,982) | ||
| Net income attributable to noncontrolling interest | 22,908 | 20,350 | 76,917 | 6,907 | 10,602 | 4,023 | ||
| Net loss available to common stockholders, diluted: | (29,945) | (26,145) | (99,038) | (7,585) | (12,078) | (105,959) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (52,853) | (46,495) | (175,955) | (14,492) | (22,680) | (109,982) | ||
| Other undisclosed comprehensive income | 574 | |||||||
| Comprehensive loss: | (52,279) | (46,495) | (175,955) | (14,492) | (22,680) | (109,982) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 22,658 | 20,350 | 76,917 | 6,907 | 10,602 | 4,023 | ||
| Comprehensive loss, net of tax, attributable to parent: | (29,621) | (26,145) | (99,038) | (7,585) | (12,078) | (105,959) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.